Department of Surgery, The Hiram C. Polk, Jr., University of Louisville, Louisville, Kentucky.
Department of Statistics, University of Kentucky, Lexington, Kentucky.
J Surg Oncol. 2020 Aug;122(2):128-133. doi: 10.1002/jso.25947. Epub 2020 Apr 25.
In women with T1-2 breast cancer and one to two positive axillary lymph nodes (LN) at low risk for recurrence, postmastectomy radiation therapy (PMRT) may provide insufficient benefit to justify its toxicity. This study evaluated the interaction of factors associated with overall survival (OS) after PMRT in these patients.
The National Cancer Database was queried for women with T1-2 breast cancer undergoing mastectomy with one to two positive LN identified on lymphadenectomy. Patients were grouped according to number of positive LN and then stratified by PMRT use. Differences in OS were evaluated.
Multivariable modeling demonstrated an interaction effect of age on the efficacy of PMRT. In patients more than or equal to 60 years old, PMRT was associated with improved survival when adjusting for age and tumor grade in patients with 1 to 2 positive LN (risk ratio = 0.62, 95% confidence interval = 0.40-0.93, P = .018). In patients less than 60 years old, tumor size and grade, but not PMRT, were associated with improved OS.
For women with T1-2 breast cancer and one to two positive LN, PMRT's association with OS is influenced by age, tumor grade, and number of positive LN. PMRT appears to be associated with improvements in OS in older patients, but not younger patients, regardless of tumor size or nodal status.
对于 T1-2 期乳腺癌且腋窝淋巴结(LN)有 1-2 个阳性且复发风险低的女性,乳房切除术(PMRT)后放射治疗可能无法提供足够的益处,无法证明其毒性是合理的。本研究评估了与这些患者 PMRT 后总生存(OS)相关的因素的相互作用。
国家癌症数据库查询了接受过淋巴结清扫术的 T1-2 期乳腺癌乳房切除术且有 1-2 个阳性 LN 的女性。根据阳性 LN 的数量将患者分组,然后根据 PMRT 的使用情况进行分层。评估 OS 的差异。
多变量模型显示年龄对 PMRT 疗效有交互作用。在年龄大于或等于 60 岁的患者中,在调整年龄和肿瘤分级后,PMRT 与 1-2 个阳性 LN 患者的生存改善相关(风险比=0.62,95%置信区间=0.40-0.93,P=0.018)。在年龄小于 60 岁的患者中,肿瘤大小和分级,而不是 PMRT,与 OS 的改善相关。
对于 T1-2 期乳腺癌且有 1-2 个阳性 LN 的女性,PMRT 与 OS 的关联受年龄、肿瘤分级和阳性 LN 数量的影响。PMRT 似乎与老年患者 OS 的改善相关,而与年轻患者无关,无论肿瘤大小或淋巴结状态如何。